Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 470-080-3
CAS number: -
OralIn a 28 -day repeated dose toxicity study with 1-((2-Butyloctyloxymethyl)-2-(3,4-dihydro-isoquinolinium-2-yl)ethyl)sulfate no substance-related adverse findings were obtained. Therefore, the no-observed-adverse-effect level (NOAEL) was 1000 mg/kg body weight per day in both sexes.Dermal No data available.InhalationNo data available.
There is a reliable study available to
assess the toxicity of the test substance after subacute oral dosing.
In a 28 -day repeated dose toxicity study,
was administered to male and female Wistar rats by gavage at dose levels
of 0 (vehicle control), 100, 300 and 1000 mg/kg body weight per day over
a period of 4 weeks. Control and high dose groups consisted of each 10
animals per sex, whereas low and mid dose groups consisted of each 5
animals per sex. After 4 weeks of treatment 5 animals per sex of alt
dose groups were sacrificed (main groups). The remaining 5 animals per
sex of control and high dose groups were maintained for another 14 days
without administration of the test substance (recovery groups). The dose
volume was 5 ml/kg bw.
Food consumption and body weight were
determined weekly. The animals were examined for signs of toxicity or
mortality at least once a day. Detailed clinical examinations in an open
field were conducted prior to the start of the administration period and
weekly thereafter. Functional observational battery (FOB) as well as
measurement of motor activity (MA) was carried out at the end of the
treatment period. Clinicochemical, hematological examinations and
urinalyses were performed towards the end of the administration period.
At the end of the study all animals were assessed by gross pathology,
followed by histopathological examinations.
No substance related effects were observed
in any treatment group. Concerning Clinical Pathology no
treatment-related adverse findings were measured. Moreover, regarding
Pathology, there were no substance-related weight changes, gross lesions
or microscopic findings in male and female Wistar rats observed after 4
weeks of treatment. In addition, during the recovery period also no
effects were noted.
In conclusion, under the conditions of the
present study no substance-related adverse findings were obtained.
Therefore, the no-observed-adverse-effect level (NOAEL) was 1000 mg/kg
body weight per day in both sexes.
No data available.
No data available.
There were no toxic systemic effects
observed after subacute oral dosage of <= 1000 mg test substance/kg
bw/d. Therefore, there is no indication given for classification regarding
repeated dose toxicity according to 67/548/EEC and Regulation (EC) No 1272/2008
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again